Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

500 women with advanced uterine cancer to have tumors genetically profiled

NCT ID NCT07041606

Knowledge-focused Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 09, 2026 · Updated 6 times

Summary

This study looks at the genetic makeup of advanced endometrial cancer in 500 women in Russia. Researchers will test tumor samples for specific gene changes to see how common they are and what treatments patients receive. The goal is to gather information, not to test a new treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 500 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2025

Expected to finish

Jun 2027

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Study population will consist of patients with newly diagnosed aggressive subtypes of advanced (III-IV stages) EC, with available medical history, biopsy or post-operative archival FFPE tumor samples (blocks). It is estimated that approximately 500 patients will be enrolled in about 30 sites.

Ages

18 years and older

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Female patients aged ≥ 18 years old; 2. Signed ICF, including consent for archival FFPE tumor tissue block testing; 3. Newly diagnosed, histologically confirmed, advanced (III-IV stage) EC, with the date of diagnosis of histologically confirmed disease within 4 months before inclusion; 4. Endometrioid type G3 or any non-endometrioid histological type of EC (such as serous carcinoma, clear cell carcinoma, mixed carcinoma, undifferentiated and dedifferentiated carcinoma, carcinosarcoma, others); 5. The presence of biopsy or postoperative archival FFPE tumor sample (block); 6. Availability of source medical documentation. Exclusion Criteria: 1\. Patients participating in clinical (interventional) studies since the diagnosis of histologically confirmed, advanced EC.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Endometrial cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Endometrial cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    18 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Research Site

    RECRUITING

    Arkhangelsk, Russia

  • Research Site

    RECRUITING

    Barnaul, Russia

  • Research Site

    RECRUITING

    Chelyabinsk, Russia

  • Research Site

    RECRUITING

    Irkutsk, Russia

  • Research Site

    RECRUITING

    Izhevsk, Russia

  • Research Site

    RECRUITING

    Krasnodar, Russia

  • Research Site

    RECRUITING

    Krasnoyarsk, Russia

  • Research Site

    RECRUITING

    Moscow, Russia

  • Research Site

    RECRUITING

    Murmansk, Russia

  • Research Site

    NOT_YET_RECRUITING

    Obninsk, Russia

  • Research Site

    RECRUITING

    Saint Petersburg, Russia

  • Research Site

    NOT_YET_RECRUITING

    Severodvinsk, Russia

  • Research Site

    RECRUITING

    Sochi, Russia

  • Research Site

    RECRUITING

    Tomsk, Russia

  • Research Site

    RECRUITING

    Tver', Russia

  • Research Site

    RECRUITING

    Ufa, Russia

  • Research Site

    WITHDRAWN

    Vladivostok, Russia

  • Research Site

    RECRUITING

    Yaroslavl, Russia

  • Research Site

    RECRUITING

    Yekaterinburg, Russia

More trials for these conditions

Other studies related to the condition(s) this trial covers.